Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKCA Akcea Therapeutics	$18.17	$18.16	$8.00 ▼ $21.70	$1.85B	1.45	361,806 shs	N/A
BBIO BridgeBio Pharma	$39.78 +0.3%	$35.29	$21.62 ▼ $40.40	$7.55B	1.1	2.49 million shs	2.64 million shs
CORT Corcept Therapeutics	$70.06 -1.6%	$71.48	$28.04 ▼ $117.33	$7.43B	0.19	1.15 million shs	1.01 million shs
VRNA Verona Pharma	$92.20 -0.3%	$71.08	$14.14 ▼ $93.74	$7.48B	0.21	1.32 million shs	754,182 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKCA Akcea Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
BBIO BridgeBio Pharma	+0.33%	+3.00%	+18.18%	+20.66%	+38.70%
CORT Corcept Therapeutics	-1.57%	+0.66%	-1.10%	+25.08%	+114.64%
VRNA Verona Pharma	-0.32%	+9.32%	+37.12%	+50.19%	+525.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKCA Akcea Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	4.6121 of 5 stars	4.5	2.0	0.0	3.9	2.7	3.3	0.6
CORT Corcept Therapeutics	4.5899 of 5 stars	3.5	1.0	0.0	4.2	2.7	4.2	1.9
VRNA Verona Pharma	2.1019 of 5 stars	2.6	3.0	0.0	0.0	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKCA Akcea Therapeutics	0.00	N/A	N/A	N/A
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.36	44.20% Upside
CORT Corcept Therapeutics	3.00	Buy	$138.25	97.33% Upside
VRNA Verona Pharma	3.10	Buy	$87.44	-5.16% Downside

Current Analyst Ratings Breakdown

Latest AKCA, CORT, BBIO, and VRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	VRNA Verona Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $100.00
6/11/2025	VRNA Verona Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$95.00 ➝ $110.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
6/2/2025	VRNA Verona Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$85.00 ➝ $90.00
5/6/2025	CORT Corcept Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$135.00
5/6/2025	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00
4/30/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$46.00 ➝ $63.00
4/30/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $55.00
4/30/2025	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $72.00
4/30/2025	VRNA Verona Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$93.00 ➝ $107.00
4/30/2025	VRNA Verona Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$75.00 ➝ $85.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKCA Akcea Therapeutics	$488.54M	3.78	$0.51 per share	35.54	$5.78 per share	3.14
BBIO BridgeBio Pharma	$127.42M	59.28	N/A	N/A	($7.71) per share	-5.16
CORT Corcept Therapeutics	$685.45M	10.84	$1.03 per share	67.96	$4.92 per share	14.24
VRNA Verona Pharma	$118.54M	63.07	N/A	N/A	$3.10 per share	29.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKCA Akcea Therapeutics	$40.77M	$0.48	N/A	N/A	N/A	-12.34%	-8.94%	-8.02%	N/A
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-241.44%	N/A	-75.69%	7/30/2025 (Estimated)
CORT Corcept Therapeutics	$106.14M	$1.16	55.60	37.87	N/A	22.35%	24.54%	20.24%	8/4/2025 (Estimated)
VRNA Verona Pharma	-$54.37M	-$2.00	N/A	3,073.33	N/A	N/A	-79.54%	-43.49%	8/14/2025 (Estimated)

Latest AKCA, CORT, BBIO, and VRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million
4/29/2025	Q1 2025	VRNA Verona Pharma	-$0.22	$0.27	+$0.49	-$0.16	$41.47 million	$98.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKCA Akcea Therapeutics	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKCA Akcea Therapeutics	N/A	12.17	11.78
BBIO BridgeBio Pharma	N/A	4.67	4.67
CORT Corcept Therapeutics	0.01	3.70	3.64
VRNA Verona Pharma	0.93	13.03	12.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKCA Akcea Therapeutics	19.27%
BBIO BridgeBio Pharma	99.85%
CORT Corcept Therapeutics	93.61%
VRNA Verona Pharma	85.88%

Insider Ownership

Company	Insider Ownership
AKCA Akcea Therapeutics	1.50%
BBIO BridgeBio Pharma	18.20%
CORT Corcept Therapeutics	20.80%
VRNA Verona Pharma	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKCA Akcea Therapeutics	248	101.60 million	N/A	Optionable
BBIO BridgeBio Pharma	400	189.88 million	143.29 million	Optionable
CORT Corcept Therapeutics	300	106.05 million	83.30 million	Optionable
VRNA Verona Pharma	30	81.08 million	76.10 million	Optionable

AKCA, CORT, BBIO, and VRNA Headlines

Recent News About These Companies

Verona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in Stock

June 14 at 7:35 AM | insidertrades.com

Cantor Fitzgerald Predicts Verona Pharma FY2025 Earnings

June 14 at 2:14 AM | americanbankingnews.com

Verona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in Stock

June 13 at 6:11 PM | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 400,000 Shares

June 13 at 6:11 PM | marketbeat.com

Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch

June 13 at 3:50 PM | insidermonkey.com

Cantor Fitzgerald Estimates Verona Pharma FY2025 Earnings

June 13 at 6:07 AM | marketbeat.com

Cantor Fitzgerald Comments on Verona Pharma FY2026 Earnings

June 13 at 3:09 AM | americanbankingnews.com

Cantor Fitzgerald Issues Positive Forecast for Verona Pharma (NASDAQ:VRNA) Stock Price

June 13 at 1:50 AM | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Trading Up 4.5% on Analyst Upgrade

June 13 at 1:17 AM | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Price Target Raised to $110.00 at Jefferies Financial Group

June 12 at 3:57 AM | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Shares Up 4.5% on Analyst Upgrade

June 11 at 12:31 PM | marketbeat.com

Jefferies Financial Group Issues Positive Forecast for Verona Pharma (NASDAQ:VRNA) Stock Price

June 11 at 10:37 AM | marketbeat.com

Verona Pharma (NASDAQ:VRNA) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

June 11 at 10:37 AM | marketbeat.com

Analysts Offer Predictions for Verona Pharma FY2026 Earnings

June 11 at 8:45 AM | marketbeat.com

Verona Pharma (NASDAQ:VRNA) Hits New 52-Week High - Here's What Happened

June 10, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) Receives Consensus Rating of "Buy" from Analysts

June 10, 2025 | marketbeat.com

GAMMA Investing LLC Has $7.41 Million Stock Holdings in Verona Pharma plc (NASDAQ:VRNA)

June 9, 2025 | marketbeat.com

RFG Advisory LLC Invests $1.48 Million in Verona Pharma plc (NASDAQ:VRNA)

June 5, 2025 | marketbeat.com

Hennion & Walsh Asset Management Inc. Purchases 5,766 Shares of Verona Pharma plc (NASDAQ:VRNA)

June 3, 2025 | marketbeat.com

Hamilton Lane Advisors LLC Takes $1.65 Million Position in Verona Pharma plc (NASDAQ:VRNA)

June 3, 2025 | marketbeat.com

Verona Pharma (NASDAQ:VRNA) Hits New 1-Year High After Analyst Upgrade

June 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKCA, CORT, BBIO, and VRNA Company Descriptions

Akcea Therapeutics NASDAQ:AKCA

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

BridgeBio Pharma NASDAQ:BBIO

$39.78 +0.13 (+0.33%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$40.72 +0.94 (+2.36%)

As of 06/13/2025 07:45 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Corcept Therapeutics NASDAQ:CORT

$70.06 -1.12 (-1.57%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$70.12 +0.06 (+0.09%)

As of 06/13/2025 07:53 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Verona Pharma NASDAQ:VRNA

$92.20 -0.30 (-0.32%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$92.00 -0.20 (-0.22%)

As of 06/13/2025 07:57 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time